Adjuvant chemotherapy for non-small cell lung cancer

Tatsuro Okamoto, Yukito Ichinose

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Recently, several randomized trials with a large number of enrolled patients have shown that postoperative adjuvant treatment improves survival among patients with completely resected non-small cell lung cancer (NSCLC). Platinum-based chemotherapy has been reported to be effective for patients with postoperative stage I to IIIA NSCLC in western countries. On the other hand, uracil-tegafur was also shown to improve survival among patients with stage I adenocarcinoma in Japan. We reviewed the results of recent randomized trials and meta-analyses, and discuss the current role and problems related to adjuvant chemotherapy in NSCLC.

Original languageEnglish
Pages (from-to)1985-1990
Number of pages6
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume33
Issue number13
Publication statusPublished - Jan 1 2006

Fingerprint

Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Tegafur
Survival
Uracil
Platinum
Meta-Analysis
Japan
Adenocarcinoma
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Adjuvant chemotherapy for non-small cell lung cancer. / Okamoto, Tatsuro; Ichinose, Yukito.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 33, No. 13, 01.01.2006, p. 1985-1990.

Research output: Contribution to journalReview article

Okamoto, T & Ichinose, Y 2006, 'Adjuvant chemotherapy for non-small cell lung cancer', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 33, no. 13, pp. 1985-1990.
Okamoto, Tatsuro ; Ichinose, Yukito. / Adjuvant chemotherapy for non-small cell lung cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2006 ; Vol. 33, No. 13. pp. 1985-1990.
@article{6c4b4659056141f6a1fcfa38ab31bab6,
title = "Adjuvant chemotherapy for non-small cell lung cancer",
abstract = "Recently, several randomized trials with a large number of enrolled patients have shown that postoperative adjuvant treatment improves survival among patients with completely resected non-small cell lung cancer (NSCLC). Platinum-based chemotherapy has been reported to be effective for patients with postoperative stage I to IIIA NSCLC in western countries. On the other hand, uracil-tegafur was also shown to improve survival among patients with stage I adenocarcinoma in Japan. We reviewed the results of recent randomized trials and meta-analyses, and discuss the current role and problems related to adjuvant chemotherapy in NSCLC.",
author = "Tatsuro Okamoto and Yukito Ichinose",
year = "2006",
month = "1",
day = "1",
language = "English",
volume = "33",
pages = "1985--1990",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "13",

}

TY - JOUR

T1 - Adjuvant chemotherapy for non-small cell lung cancer

AU - Okamoto, Tatsuro

AU - Ichinose, Yukito

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Recently, several randomized trials with a large number of enrolled patients have shown that postoperative adjuvant treatment improves survival among patients with completely resected non-small cell lung cancer (NSCLC). Platinum-based chemotherapy has been reported to be effective for patients with postoperative stage I to IIIA NSCLC in western countries. On the other hand, uracil-tegafur was also shown to improve survival among patients with stage I adenocarcinoma in Japan. We reviewed the results of recent randomized trials and meta-analyses, and discuss the current role and problems related to adjuvant chemotherapy in NSCLC.

AB - Recently, several randomized trials with a large number of enrolled patients have shown that postoperative adjuvant treatment improves survival among patients with completely resected non-small cell lung cancer (NSCLC). Platinum-based chemotherapy has been reported to be effective for patients with postoperative stage I to IIIA NSCLC in western countries. On the other hand, uracil-tegafur was also shown to improve survival among patients with stage I adenocarcinoma in Japan. We reviewed the results of recent randomized trials and meta-analyses, and discuss the current role and problems related to adjuvant chemotherapy in NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=33846921594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846921594&partnerID=8YFLogxK

M3 - Review article

C2 - 17197740

AN - SCOPUS:33846921594

VL - 33

SP - 1985

EP - 1990

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 13

ER -